

Anja Strangfeld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5378834/publications.pdf>

Version: 2024-02-01

56
papers

6,972
citations

185998

28
h-index

138251

58
g-index

63
all docs

63
docs citations

63
times ranked

7584
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e114-e114.	0.5	2
2	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Mulhearn et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e116-e116.	0.5	87
3	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Rosenbaum et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e139-e139.	0.5	2
4	Response to: "Correspondence on "EULAR recommendations for a core data set for pregnancy registries in rheumatology" by De Cock et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e45-e45.	0.5	4
5	Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 41-47.	0.5	39
6	SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 145-150.	0.5	30
7	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114.	1.0	9
8	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 780-785.	0.5	12
9	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 695-709.	0.5	130
10	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.5	49
11	Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 998-1005.	0.5	12
12	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	1.8	34
13	Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the "JAK-pot" collaboration. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1358-1366.	0.5	48
14	Maternal and infant outcomes in pregnancies of women with axial spondyloarthritis compared with matched controls: results from nationwide health insurance data. <i>RMD Open</i> , 2022, 8, e002146.	1.8	5
15	EULAR recommendations for a core data set for pregnancy registries in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 49-56.	0.5	36
16	Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. <i>RMD Open</i> , 2021, 7, e001464.	1.8	82
17	EULAR COVID-19 registry: lessons learnt and future considerations. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1110-1115.	0.5	6
18	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.5	151

#	ARTICLE	IF	CITATIONS
19	Pregnancy in women with psoriatic arthritis: A systematic literature review of disease activity and adverse pregnancy outcomes. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 530-538.	1.6	11
20	Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. <i>Zeitschrift Fur Rheumatologie</i> , 2021, 80, 33-48.	0.5	13
21	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.5	496
22	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	2.8	86
23	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2021, 3, e855-e864.	2.2	38
24	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. <i>RMD Open</i> , 2021, 7, .	1.8	6
25	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. <i>RMD Open</i> , 2021, 7, e001818.	1.8	4
26	TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. <i>RMD Open</i> , 2021, 7, e001896.	1.8	22
27	Mobile Responsive App – A Useful Additional Tool for Data Collection in the German Pregnancy Register Rhekiss?. <i>Frontiers in Medicine</i> , 2021, 8, 773836.	1.2	3
28	Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 1916-1926.	0.9	24
29	Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT. <i>RMD Open</i> , 2020, 6, e001290.	1.8	18
30	National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. <i>RMD Open</i> , 2020, 6, e001332.	1.8	44
31	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866.	0.5	908
32	Methotrexate: what are the true risks of treatment?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1267-1268.	0.5	4
33	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.5	1,860
34	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology, The</i> , 2020, 2, e250-e253.	2.2	172
35	Incidence of facial nerve palsies stratified by DMARD treatment in patients with rheumatoid arthritis: data from the RABBIT register. <i>RMD Open</i> , 2020, 6, e001403.	1.8	5
36	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1160-1166.	0.5	34

#	ARTICLE	IF	CITATIONS
37	OPO226â€¦SOLID TUMOUR OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY. , 2019, , .		2
38	European Network of Pregnancy Registers in Rheumatology (EuNeP)â€™an overview of procedures and data collection. Arthritis Research and Therapy, 2019, 21, 241.	1.6	19
39	Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts. Seminars in Arthritis and Rheumatism, 2019, 48, 976-982.	1.6	20
40	Rheumatoid arthritis treatment in patients with a history of cancer. Current Opinion in Rheumatology, 2018, 30, 288-294.	2.0	15
41	Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort. Rheumatology International, 2018, 38, 579-587.	1.5	13
42	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Annals of the Rheumatic Diseases, 2017, 76, 386-391.	0.5	150
43	Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Annals of the Rheumatic Diseases, 2017, 76, 2025-2030.	0.5	77
44	Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 183.	1.6	51
45	Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases. Arthritis Research and Therapy, 2016, 18, 149.	1.6	36
46	Primary and secondary patient data in contrast: the use of observational studies like RABBIT. Clinical and Experimental Rheumatology, 2016, 34, S79-S86.	0.4	8
47	Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT. Rheumatology, 2015, 54, 1858-1866.	0.9	56
48	Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFÎ± inhibitors and rituximab. Annals of the Rheumatic Diseases, 2015, 74, 415-421.	0.5	217
49	Sustainability of Rituximab Therapy in Different Treatment Strategies: Results of a 3â€¥Year Followup of a German Biologics Register. Arthritis Care and Research, 2014, 66, 1627-1633.	1.5	21
50	Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. Rheumatology, 2011, 50, 146-151.	0.9	18
51	How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician- and patient-reported adverse events in patients with rheumatoid arthritis observed in the German biologics register. Rheumatology, 2011, 50, 152-160.	0.9	35
52	Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Research and Therapy, 2010, 12, R5.	1.6	224
53	Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Antiâ€™TNF-Î± Agents. JAMA - Journal of the American Medical Association, 2009, 301, 737.	3.8	485
54	Does tumor necrosis factor Î± inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. Arthritis and Rheumatism, 2008, 58, 667-677.	6.7	191

#	ARTICLE	IF	CITATIONS
55	Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trials. Arthritis and Rheumatism, 2006, 54, 3399-3407.	6.7	210
56	Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis and Rheumatism, 2005, 52, 3403-3412.	6.7	620